Drug Approval | October 30, 2022
USFDA issues Form 483 for Parawada unit of Laurus Labs
The observation is procedural in nature and the company will address the observation within stipulated timelines.
The observation is procedural in nature and the company will address the observation within stipulated timelines.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The CRL did not identify any outstanding scientific issues with the product.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Subscribe To Our Newsletter & Stay Updated
